Cargando…

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion

A higher concentration of apolipoprotein A-I (ApoA-I) is associated with increased high density lipoprotein functionality and reverse cholesterol transport (RCT). A promising strategy to prevent cardiovascular diseases is therefore to improve RCT by increasing de novo ApoA-I production. Since experi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tayyeb, Jehad Z., Popeijus, Herman E., van de Sanden, Janna, Zwaan, Willem, Mensink, Ronald P., Plat, Jogchum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181357/ https://www.ncbi.nlm.nih.gov/pubmed/35682748 http://dx.doi.org/10.3390/ijms23116071

Ejemplares similares

Amoxicillin Modulates ApoA-I Transcription and Secretion, Predominantly via PPARα Transactivation Inhibition
por: Tayyeb, Jehad Z., et al.
Publicado: (2019)

Butyric Acid Added Apically to Intestinal Caco-2 Cells Elevates Hepatic ApoA-I Transcription and Rescues Lower ApoA-I Expression in Inflamed HepG2 Cells Co-Cultured in the Basolateral Compartment
por: Tayyeb, Jehad Z., et al.
Publicado: (2021)

Dietary Strategies and Novel Pharmaceutical Approaches Targeting Serum ApoA-I Metabolism: A Systematic Overview
por: Smolders, Lotte, et al.
Publicado: (2017)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

Potential Contribution of Short Chain Fatty Acids to Hepatic Apolipoprotein A-I Production
por: Popeijus, Herman E., et al.
Publicado: (2021)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

The unsolved mystery of apoA-I recycling in adipocyte
por: Wang, Shuai, et al.
Publicado: (2016)

Akt Inhibition Promotes ABCA1-Mediated Cholesterol Efflux to ApoA-I through Suppressing mTORC1
por: Dong, Fumin, et al.
Publicado: (2014)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)

Autophagy Alteration in ApoA-I Related Systemic Amyloidosis
por: Del Giudice, Rita, et al.
Publicado: (2022)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
por: Bencharif, Karima, et al.
Publicado: (2010)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023)

ApoA-1 in Diabetes: Damaged Goods
por: Ory, Daniel S., et al.
Publicado: (2010)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

ApoA-I-Mediated Lipoprotein Remodeling Monitored with a Fluorescent Phospholipid
por: Neufeld, Edward B., et al.
Publicado: (2019)

Association of serum apoA-I with in-stent restenosis in coronary heart disease
por: Wang, Xin, et al.
Publicado: (2022)

Short-Chain Fatty Acids (Except Hexanoic Acid) Lower NF-kB Transactivation, Which Rescues Inflammation-Induced Decreased Apolipoprotein A-I Transcription in HepG2 Cells
por: Tayyeb, Jehad Z., et al.
Publicado: (2020)

Iowa Mutant Apolipoprotein A-I (ApoA-I(Iowa)) Fibrils Target Lysosomes
por: Kameyama, Hirokazu, et al.
Publicado: (2016)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

Effect of apoA-I PEGylation on the Biological Fate of Biomimetic High-Density Lipoproteins
por: Pedersbæk, Dennis, et al.
Publicado: (2020)

ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
por: Daskou, Maria, et al.
Publicado: (2022)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease
por: Sorokin, Alexander V., et al.
Publicado: (2023)

LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea
por: Flores, Rhonda, et al.
Publicado: (2019)

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
por: Walldius, Göran, et al.
Publicado: (2021)

APOA1-75 G to A Substitution Associated with Severe Forms of CAD, Lower Levels of HDL and apoA-I among Northern Indians
por: Chhabra, S., et al.
Publicado: (2005)

Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition
por: Glaros, Elias N., et al.
Publicado: (2010)

Exogenous Expression of Human apoA-I Enhances Cardiac Differentiation of Pluripotent Stem Cells
por: Ng, Kwong-Man, et al.
Publicado: (2011)

Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle
por: Dalla-Riva, Jonathan, et al.
Publicado: (2013)

Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells
por: Arciello, Angela, et al.
Publicado: (2011)

ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
por: Kalayci, Arzu, et al.
Publicado: (2022)

Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia
por: Busnelli, Marco, et al.
Publicado: (2022)

An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration
por: Chen, Xun, et al.
Publicado: (2009)

Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice
por: Stenkula, Karin G., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lqd9gsgno4apegcp6tmbfc34f2